Drug Profile
Research programme: respiratory disorders therapeutics - Avalyn Pharmaceuticals
Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Genoa Pharmaceuticals
- Developer Avalyn Pharma
- Class Antifibrotics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis; Respiration disorders
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for research development in Idiopathic-pulmonary-fibrosis in USA
- 28 Apr 2022 No recent reports of development identified for research development in Respiration-disorders in USA
- 07 Mar 2018 Early research in Idiopathic pulmonary fibrosis in USA (unspecified route)